1. Home
  2. USA vs NVCR Comparison

USA vs NVCR Comparison

Compare USA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty All-Star Equity Fund

USA

Liberty All-Star Equity Fund

SELL

Current Price

$5.92

Market Cap

1.8B

Sector

Finance

ML Signal

SELL

Logo NovoCure Limited

NVCR

NovoCure Limited

SELL

Current Price

$14.36

Market Cap

2.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
USA
NVCR
Founded
N/A
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
USA
NVCR
Price
$5.92
$14.36
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $26.86
AVG Volume (30 Days)
1.1M
★ 1.2M
Earning Date
01-01-0001
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.79
EPS
★ N/A
N/A
Revenue
N/A
★ $655,353,000.00
Revenue This Year
N/A
$10.80
Revenue Next Year
N/A
$10.83
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.28
52 Week Low
$5.40
$9.82
52 Week High
$6.44
$21.45

Technical Indicators

Market Signals
Indicator
USA
NVCR
Relative Strength Index (RSI) 54.63 34.93
Support Level $5.65 $13.12
Resistance Level $6.02 $15.19
Average True Range (ATR) 0.05 0.59
MACD 0.01 -0.11
Stochastic Oscillator 83.33 22.50

Price Performance

Historical Comparison
USA
NVCR

About USA Liberty All-Star Equity Fund

Liberty All Star Equity Fund is a diversified, closed-end management investment company. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: